Oramed to present data on oral insulin formulation for Type II diabetes at Annual Meeting in Bethesda

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its work entitled "Extended exposure to an oral insulin formulation yields decreased insulin secretion in Type II diabetes subjects," will be presented at the Tenth Annual Meeting of the Diabetes Technology Society, to be held in Bethesda, Maryland this November.

"The selection of Oramed as one of the companies to present at the Diabetes Technology Conference is a great opportunity for us to appraise the diabetes science community on the important progress we have made," said Nadav Kidron, Oramed CEO.

Oramed's poster will be presented on Thursday November 11, 2010, at 5:30 PM.